Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)

(2020) Helmut Butzkueven et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Real‐life use of oral disease‐modifying treatments in Austria

(2019) Michael Guger et al.   ACTA NEUROLOGICA SCANDINAVICA

Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab

(2019) I. Dekker et al.   Multiple Sclerosis and Related Disorders

Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia

(2019) Evgeniy Evdoshenko et al.   PLoS One

Correction to: Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry

(2019) Michael Guger et al.   JOURNAL OF NEUROLOGY

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

(2018) Maria Trojano et al.   Multiple Sclerosis and Related Disorders

Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis

(2016) Luca Prosperini et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP)

(2016) Heinz Wiendl et al.   PLoS One

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

(2014) Tatiana Plavina et al.   ANNALS OF NEUROLOGY

Clinical baseline factors predict response to natalizumab: their usefulness in patient selection

(2014) Alice Laroni et al.   BMC Neurology

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results

(2014) H. Butzkueven et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Age-dependent effects on the treatment response of natalizumab in MS patients

(2014) Henrik Matell et al.   Multiple Sclerosis Journal

Clinical predictors of an optimal response to natalizumab in multiple sclerosis

(2013) João Sargento-Freitas et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis

(2010) S. Belachew et al.   EUROPEAN JOURNAL OF NEUROLOGY

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY